Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
NCT00568594
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
176
Enrollment
INDUSTRY
Sponsor class
Conditions
Coronary Heart Disease
Interventions
DRUG:
APL180
DRUG:
Placebo
Sponsor
Novartis